Uncompromising cryopreservation 

PentaHibe is a safe and effective alternative to higher concentrations of dimethyl sulfoxide (DMSO) for the cryopreservation of cells and tissues and can be used at any stage of a cell therapy application.

Cryoprotective agents minimise damage to biological material during the freezing process. For decades, 10% DMSO has been the standard in cryopreservation media. Recent studies show that this standard concentration of 10% DMSO has a cellular toxicity level that can induce epigenetic changes, and cause adverse reactions in patients such as headache, nausea, vomiting, and bradycardia. It also has a strong and offensive odour. For these reasons, there is a growing demand for cryoprotective agents with no or low levels of DMSO.

The key component in PentaHibe is pentaisomaltose®, a patented, non-penetrating carbohydrate-based cryoprotective agent that

reduces or even eliminates the use of DMSO – without compromising on safety and efficacy. And it conforms to the European Pharmacopeia (EP) and US Pharmacopeia (USP).

With PentaHibe, you gain access to comprehensive documentation for quality assurance throughout the entire development process—from cell therapy research to clinical testing and production. More than just a supplier, we are a partner offering regulatory advice and support. This includes assistance with registration, filings with authorities, and regulatory submissions.

PentaHibe is optimised for the cryopreservation of hematopoietic stem cells, mesenchymal stem cells, T cells, CHO cells and HEK cells, making it an important step towards improving safety for patients around the world.